Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 4
2009 3
2010 8
2011 5
2012 5
2013 3
2014 3
2015 5
2016 5
2017 8
2018 12
2019 10
2020 9
2021 13
2022 7
2023 9
2024 7
2025 5
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body JJ, Brandi ML, Brown J, Confavreux C, Cortet B, Drake M, Ebeling P, Eriksen EF, Fuleihan GE, Guise TA, Harvey NC, Kurth A, Langdahl B, Lems W, Matijevic R, McCloskey E, Nappi R, Palacios S, Pfeiler G, Reginster JY, Rizzoli R, Santini D, Tuzun S, Poznak CV, Villiers T, Zillikens MC, Coleman R. Hadji P, et al. J Bone Oncol. 2025 Jun 11;53:100694. doi: 10.1016/j.jbo.2025.100694. eCollection 2025 Aug. J Bone Oncol. 2025. PMID: 40726588 Free PMC article. Review.
BACKGROUND: Women with hormone-responsive breast cancer who receive adjuvant endocrine treatment with aromatase inhibitors (AI) are known to be at higher fracture risk due to a marked increase in bone resorption. In 2017, several interdisciplinary cancer and …
BACKGROUND: Women with hormone-responsive breast cancer who receive adjuvant endocrine treatment with aromatase inhibitors (AI …
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates.
Casabella A, Paladin F, Bighin C, Ottaviani S, Marelli C, Ponzano M, Signori A, Murdaca G, Cutolo M, Molfetta L, Nencioni A, Paolino S, Del Mastro L, Monacelli F. Casabella A, et al. Intern Emerg Med. 2024 Nov;19(8):2193-2199. doi: 10.1007/s11739-024-03725-1. Epub 2024 Aug 2. Intern Emerg Med. 2024. PMID: 39095675
The raising number of older patients who are diagnosed with breast cancer represents a significant medical and societal challenge. Aromatase inhibitors (AI), which are commonly utilized to treat this condition in these patients have significant adverse events on …
The raising number of older patients who are diagnosed with breast cancer represents a significant medical and societal challenge. Aromat …
Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A, Xourafa A, Rapisarda R, Castellino P. Gaudio A, et al. Endocr Metab Immune Disord Drug Targets. 2022;22(3):259-273. doi: 10.2174/1871530321666210809153152. Endocr Metab Immune Disord Drug Targets. 2022. PMID: 34370654 Review.
Apart from the appearance of arthralgias or myalgias and cardiovascular events, AI therapies, reducing already low endogenous postmenopausal estradiol levels, cause increased bone loss and increase fracture risk in postmenopausal women. OBJECTIVES: The objective of …
Apart from the appearance of arthralgias or myalgias and cardiovascular events, AI therapies, reducing already low endogenous postmenopausal …
Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Rachner TD, Göbel A, Jaschke NP, Hofbauer LC. Rachner TD, et al. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa463. doi: 10.1210/clinem/dgaa463. J Clin Endocrinol Metab. 2020. PMID: 32674135 Free article. Review.
While many of these patients have an excellent long-term prognosis, adverse effects on bone represent an emerging complication of aromatase inhibitor treatment, resulting in substantial bone loss and fragility fractures. Treatment approaches to …
While many of these patients have an excellent long-term prognosis, adverse effects on bone represent an emerging complication of …
Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM. Miyashita H, et al. Breast Cancer Res Treat. 2020 Jun;181(2):279-289. doi: 10.1007/s10549-020-05640-3. Epub 2020 Apr 21. Breast Cancer Res Treat. 2020. PMID: 32318956 Review.
PURPOSE: The data of head-to-head comparisons of the anti-fracture efficacy of bone modifying agents (BMAs) in patients with hormone receptor-positive breast cancer receiving aromatase inhibitor (AI) are not available. ...CONCLUSION: Among the bisphosphonates …
PURPOSE: The data of head-to-head comparisons of the anti-fracture efficacy of bone modifying agents (BMAs) in patients with hormone …
Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer.
Dhabhar B. Dhabhar B. Breast Cancer (Dove Med Press). 2022 Jul 14;14:163-173. doi: 10.2147/BCTT.S353332. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 35860287 Free PMC article. Review.
Zoledronic acid, alendronate, risedronate and denosumab have been the agents of choice for managing bone loss. Denosumab 60 mg is approved for gaining bone mass in women with breast cancer who are at high risk for fracture following adjuvant AI …
Zoledronic acid, alendronate, risedronate and denosumab have been the agents of choice for managing bone loss. Denos …
Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Bassatne A, Bou Khalil A, Chakhtoura M, Arabi A, Van Poznak C, El-Hajj Fuleihan G. Bassatne A, et al. Metabolism. 2022 Mar;128:154962. doi: 10.1016/j.metabol.2021.154962. Epub 2021 Dec 24. Metabolism. 2022. PMID: 34958816
BACKGROUND: Aromatase inhibitors (AIs) are routinely used to treat postmenopausal women with early-stage breast cancer. ...This systematic review and meta-analysis assesses the effect of antiresorptive drugs on AI induced bone loss in postmenopausal wo …
BACKGROUND: Aromatase inhibitors (AIs) are routinely used to treat postmenopausal women with early-stage breast cancer. ...Thi …
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Hadji P, et al. J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. J Bone Oncol. 2017. PMID: 28413771 Free PMC article. Review.
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. ...Therefore, this updated algorithm was developed to better as …
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fr …
Denosumab: in cancer treatment-induced bone loss.
Muir VJ, Scott LJ. Muir VJ, et al. BioDrugs. 2010 Dec 1;24(6):379-86. doi: 10.2165/11203310-000000000-00000. BioDrugs. 2010. PMID: 21043545 Review.
In Europe, subcutaneous denosumab is indicated for cancer treatment-induced bone loss in men with prostate cancer and in postmenopausal women with breast cancer. ...Moreover, the risk of new vertebral fracture was significantly reduced by 62% in the denosu …
In Europe, subcutaneous denosumab is indicated for cancer treatment-induced bone loss in men with prostate cancer and i …
Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis.
Zhang Y, Cui W, Hou L. Zhang Y, et al. BMC Musculoskelet Disord. 2025 Nov 12;26(1):1040. doi: 10.1186/s12891-025-09280-w. BMC Musculoskelet Disord. 2025. PMID: 41225545 Free PMC article.
OBJECTIVE: Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). ...Specifically, the denosumab group showed: (1) greater BMD improvement at all measured sk …
OBJECTIVE: Bisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by …
105 results